Skin Analytics
  • NHS
  • AI
  • Research
  • Services
    • Bupa
  • News
  • About Us
  • Careers
  • Contact Us
Select Page

Skin Analytics achieves Class IIa UKCA Mark for DERM. The UK’s first and only Class IIa certified AI dermatology device

by Tim Daly | Apr 19, 2022 | AI, Anouncement, Regulatory Certification

Achieving UKCA Class IIa certification for our DERM skin lesion analysis device is not just an important milestone in our company’s growth; it’s validation of the incredible work that our team has produced over the years. Whether it be artificial intelligence...

Skin Analytics Receives NHSX Award for AI-Based Skin Cancer Tool

by Tim Daly | Jul 14, 2021 | AI, Anouncement

Deployment of unique diagnosis aid to be boosted across the NHS Currently deployed in University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, AI platform DERM will now be available to clinicians serving millions of patients around the...

Google’s move into skin cancer analysis is great news for patients and Skin Analytics

by Tim Daly | Jun 3, 2021 | AI, Anouncement

Google’s announcement of the culmination of three years of work and a subsequent move into skin disease analysis at their developer conference earlier this week has led to a number of people approaching me to ask what does this mean for Skin Analytics? Spoiler alert:...

Skin Analytics response to NHS AI Code of Conduct

by Editor | Mar 3, 2020 | AI, Anouncement, Blog, Skin Cancer

In July 2019 the Department of Health and Social Care and NHS England published a new code of conduct for the use of digital technology in health and care. As a company at the forefront of using AI algorithms to identify Skin Cancer, we know that AI provides...

Skin Analytics Awarded ISO 13485 Certification

by Editor | Mar 3, 2020 | Anouncement, Blog, Regulatory Certification, Skin Cancer

Skin Analytics is delighted to announce that we are now ISO 13485:2016 certified. ISO 13485:2016 is an internationally recognised quality standard for medical devices and is a pre-requisite for registration as a class II medical device under the MDR. This...

Response: BMJ article: B2C apps not up to standard.

by Tim Daly | Feb 13, 2020 | AI, Anouncement, Blog, Research

In February 2020, skin cancer researchers released a paper calling into question the quality of evidence behind the current crop of consumer-facing skin cancer apps. Given that we’re focused on the integration of our AI into health providers like the NHS and Vitality...
« Older Entries

Categories

  • AI
  • Anouncement
  • Blog
  • Funding
  • Regulatory Certification
  • Research
  • Skin Cancer
  • Testimonial
  • Uncategorized

Recent Posts

  • Skin Analytics achieves Class IIa UKCA Mark for DERM. The UK’s first and only Class IIa certified AI dermatology device
  • The Story So Far…
  • Discussing the systematic review of skin cancer datasets in The Lancet: Skin Analytics response.
  • Skin Analytics Receives NHSX Award for AI-Based Skin Cancer Tool
  • Google’s move into skin cancer analysis is great news for patients and Skin Analytics
Skin Analytics Footer Logo

UNITED KINGDOM
Skin Analytics Ltd is a UK registered company.
Number 07919560.
Registered office: Salisbury House, Station Road, Cambridge, CB1 2LA.

Our Service

  • Terms And Conditions
  • Privacy Policy
  • Complaints Policy
Skin Analytics Footer Logo

AUSTRALIA
Skin Analytics Pty Ltd.
ABN 32 619 047 728.
ACN 619 047 728.
Registered Office: 7 Southport St, West Leederville WA 6007

  • Facebook
  • Twitter
Copyright © 2012 - 2021 Skin Analytics - - - - - (USA) Caution -- DERM is an Investigational Device, Limited by United States Law to Investigational Use
×

Our AI technology, DERM is now a Class IIa UKCA certified medical device. This clearance allows Skin Analytics to continue to innovate skin cancer pathways with our partners. This is the next step for Skin Analytics and our technology but it is by no means the end. We will continue to work with regulators as standards of AI in clinical pathways evolve and develop, driving towards clinical excellence.

Find out more